---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-052317"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:24:25.612336+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biostage settles wrongful death litigation; to issue $4M convertible preferred to HBIO

## Summary
- Biostage settles 2017 wrongful death suit; total costs estimated at ~$6M, $5.7M unpaid.
- HBIO to pay $4M of costs; Biostage will issue $4M of 8% convertible preferred stock.
- Preferred converts automatically upon qualified offering (e.g., NASDAQ uplisting or $4M+ private placement) at offering price.
- Remaining ~$1.7M in costs and future legal expenses still payable by Biostage or indemnified to HBIO.
- Neither party admits liability; claims dismissed with prejudice.

## SEC filing metadata
- accession: 0001104659-22-052317
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000110465922052317/0001104659-22-052317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000110465922052317/tm2213848d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-052317
- JSON: https://secwatch.observer/filing/0001104659-22-052317.json
- Plain text: https://secwatch.observer/filing/0001104659-22-052317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.